Immix Biopharma, Inc.
General ticker "IMMX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $64.9M (TTM average)
Immix Biopharma, Inc. follows the US Stock Market performance with the rate: 46.9%.
Estimated limits based on current volatility of 6.8%: low 3.91$, high 4.48$
Factors to consider:
- Total employees count: 17 (+54.5%) as of 2023
- Top business risk factors: Cybersecurity threats, Regulatory and compliance, Geopolitical risks, Market competition, Labor/talent shortage/retention
- Current price 49.3% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.31$, 3.24$]
- 2025-12-31 to 2026-12-31 estimated range: [1.13$, 2.86$]
Financial Metrics affecting the IMMX estimates:
- Positive: with PPE of -2.8 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -23.51 <= 0.33
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: -4.48 < Investing cash flow per share per price, % of -1.90
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: 41.86 < Shareholder equity ratio, % of 57.74 <= 63.39
Short-term IMMX quotes
Long-term IMMX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $8.22MM | $16.14MM | $22.67MM |
| Operating Income | $-8.22MM | $-16.14MM | $-22.67MM |
| Non-Operating Income | $-0.00MM | $0.57MM | $1.02MM |
| Interest Expense | $0.00MM | $0.00MM | $0.00MM |
| R&D Expense | $4.20MM | $8.74MM | $11.29MM |
| Income(Loss) | $-8.22MM | $-15.57MM | $-21.66MM |
| Taxes | $0.01MM | $0.03MM | $0.04MM |
| Profit(Loss)* | $-8.23MM | $-15.43MM | $-21.61MM |
| Stockholders Equity | $13.16MM | $16.41MM | $13.25MM |
| Assets | $14.91MM | $19.93MM | $22.95MM |
| Operating Cash Flow | $-7.41MM | $-11.37MM | $-14.60MM |
| Capital expenditure | $0.00MM | $0.05MM | $1.18MM |
| Investing Cash Flow | $0.00MM | $-0.05MM | $-1.18MM |
| Financing Cash Flow | $3.23MM | $15.46MM | $15.95MM |
| Earnings Per Share** | $-0.59 | $-0.89 | $-0.76 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.